Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adverse cytogenetics trump molecular risk in NPM1-mutated AML

Key clinical point: A pooled analysis suggests that adverse cytogenetics negatively impact outcomes in patients with NPM1mut/FLT3-ITDneg/low acute myeloid leukemia (AML).

Major finding: Adverse cytogenetics among patients with NPM1mut/FLT3-ITDneg/low AML were associated with inferior complete remission rates (66.3%), compared with patients with normal karyotype or intermediate-risk cytogenetic abnormalities (87.7% and 86.0%, respectively; P less than .001).

Study details: A pooled analysis of nine international AML registries evaluating 2,426 patients with NPM1mut/FLT3-ITDneg/low AML.

Disclosures: The study was funded by the University of Munster Medical School, the German Research Foundation, the French government, the Ministry of Health of the Czech Republic, and others. The authors reported financial affiliations with numerous pharmaceutical companies.


Angenendt L et al. J Clin Oncol. 2019 Oct 10;37(29):2632-42.